Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults

Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults

Abstract Background GSK has modified the licensed monovalent bulk manufacturing process for its split-virion inactivated quadrivalent influenza vaccine (IIV4) to harmonize the process among different strains, resulting in an increased number of finished vaccine doses, while compensating for the chan...

Full description

Bibliographic Details
Main Authors: Carine Claeys, Mamadou Drame, José García-Sicilia, Khalequ Zaman, Alfonso Carmona, Phu My Tran, Mariano Miranda, Federico Martinón-Torres, Franck Thollot, Michael Horn, Tino F. Schwarz, Ulrich Behre, José M. Merino, Iwona Sadowska-Krawczenko, Henryk Szymański, Peter Schu, Elisabeth Neumeier, Ping Li, Varsha K. Jain, Bruce L. Innis
Format: Article
Language:English
Published: BMC 2018-04-01
Series:BMC Infectious Diseases
Subjects:
Adults
Infants
Children
Quadrivalent
Influenza vaccine
Investigational
Online Access:http://link.springer.com/article/10.1186/s12879-018-3079-8

Internet

http://link.springer.com/article/10.1186/s12879-018-3079-8

Similar Items